1447: Serum Cytokine Profiling Reveals Elevated Levels of S100A8/A9 and MMP-9 in Systemic Lupus Erythematosus Patients with Cognitive Impairment Independently of Disease Activity and Inflammatory Markers

Carolina Munoz¹, Michelle Barraclough², Juan Pablo Diaz-Martinez¹, Jiandong Su¹, Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, May Choi⁶, Dennisse Bonilla¹, Simone Appenzeller⁷, Patricia Katz⁸, Dorcas Beaton⁹, Robin Green⁵, Joan Wither¹⁰ and Zahi Touma¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁷Unicamp, Campinas, São Paulo, Brazil, ⁸UCSF, San Rafael, CA, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric lupus(NPSLE), which may occur in the absence of active Systemic Lupus Erythematosus (SLE) and negatively impacts patients' daily functioning and health-related quality of life. Therefore, identifying patients at high risk of developing CI is essential to prevent the accrual of damage and disability. However, its pathogenesis is largely unknown, and currently, biomarkers for the risk of CI are lacking. Here we investigated whether SLE patients with CI have elevated serum levels of cytokines that previous studies have suggested to have a potential pathogenic role in NPSLE.

Methods: 291 individuals between 18-65 years old who met the 2019 EULAR/ACR classification criteria for SLE were included. Cognitive assessment was performed by a psychometrist and included the comprehensive 1-hour ACR Neuropsychological Battery (ACR-NB), which encompasses 19 cognitive tests representing six cognitive domains. The serum levels of nine cytokines (IL-10, IL-6, IFN-g, TNF-a, TWEAK, MMP-9, S100 A8/A9, NGAL, and S100B) were determined using ELISA kits (R&D Systems). Differences in the serum levels of the cytokine profile between patients with and without CI (defined as a z-score of ≤-1.5 in two or more domains in the ACR-NB) were determined by the Mann-Whitney U test. Correlations were assessed using Spearman's rank correlation coefficient and the association of the different cytokine levels with each CI test score by logistic regression.

Results: Forty percent of the patients (n=116) had CI. While no differences in the demographic characteristics and disease activity were observed between patients with and without CI, serum levels of S100A8/A9 and, to a lesser extent, MMP-9 were significantly higher in patients with CI (Figure 1). When the ACR-NB's domains were examined individually, patients with impaired simple attention and processing; visual-spatial construction; learning and memory; or executive function also had significantly higher S100A8/A9 than those without impairment (Figure 2). Indicative of probable collinearity, S100A8/A9 and MMP-9 moderately correlated with each other (Rho=0.52, p< 0.0001) and both correlated with NGAL (Rho=0.64, p< 0.0001; Rho=0.56, p< 0.0001, respectively). S100A8/A9 had the strongest relationship with multiple CI tests by logistic regression. The serum levels of S100A8/A9 and MMP-9 did not correlate with TNF-a, IL-6, hs-CRP, or disease activity as determined by the SLE Disease Activity Index-2000 (SLEDAI-2K).

Conclusion: Among the multiple cytokines measured, only the heterodimer of the calcium-binding proteins S100A8 and S100A9 and MMP-9 were found to be increased in SLE patients with CI. The lack of correlation with the levels of other pro-inflammatory markers and its differential association with distinct cognitive domains may indicate that, in the setting of CI, S100A8/A9 mediates a regional neuroinflammatory response rather than systemic pro-inflammation. These results open new avenues to study the role of S100A8/A9 and MMP-9 in CI in adults with SLE.
Figure 1. Serum levels of S100A8/A9 and, to a lesser extent, MMP-9 were significantly higher in patients with CI

Figure 2. Serum levels of S100A8/A9 according to the ACR-NB’s cognitive domains
Disclosures: C. Munoz, None; M. Barraclough, None; J. Diaz-Martinez, None; J. Su, None; K. Bingham, None; M. Kakvan, None; M. Tartaglia, None; L. Ruttan, None; M. Choi, AstraZeneca, MitogenDx, mallinckrodt, Janssen, AbbVie/Abbott, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol-Myers Squibb(BMS), Celltrion, Ferring, Fresenius Kabi, McKesson, Mylan, Takeda, Pendopharm, Pfizer, Roche; D. Bonilla, None; S. Appenzeller, None; P. Katz, None; D. Beaton, None; R. Green, None; J. Wither, AstraZeneca, Pfizer; Z. Touma, None.